Patients' prognostic factors of miRNA screening cohort
| . | n/% . |
|---|---|
| Binet stage | |
| A | 33/50 (66.0 %) |
| B | 11/50 (22.0%) |
| C | 6/50 (12.0%) |
| Cytogenetics | |
| Normal | 12/45 (26.6%) |
| del13q14 | 25/45 (55.5%) |
| Homozygous del13q14 | 6/45 (13.2%) |
| Trisomy 12 | 3/45 (6.6%) |
| del11q | 3/45 (6.6%) |
| del17p | 1/45 (2.2%) |
| . | n/% . |
|---|---|
| Binet stage | |
| A | 33/50 (66.0 %) |
| B | 11/50 (22.0%) |
| C | 6/50 (12.0%) |
| Cytogenetics | |
| Normal | 12/45 (26.6%) |
| del13q14 | 25/45 (55.5%) |
| Homozygous del13q14 | 6/45 (13.2%) |
| Trisomy 12 | 3/45 (6.6%) |
| del11q | 3/45 (6.6%) |
| del17p | 1/45 (2.2%) |
Clinical and molecular features including cytogenetic analysis by FISH of 50 patients being diagnosed with CLL were assessed before miRNA profiling was performed.